Dias Sara P, Brouwer Matthijs C, van de Beek Diederik
Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Department of Neurology, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal.
Br J Clin Pharmacol. 2020 Feb;86(2):386-391. doi: 10.1111/bcp.14163. Epub 2020 Jan 7.
Inflammatory markers have been found at higher concentrations in women than men with bacterial meningitis. To investigate sex-based differences in the response to dexamethasone, we performed a post hoc analysis of a double-blind, randomised multicentre trial of dexamethasone (10 mg, 4 times daily for 4 days) vs placebo in adults with bacterial meningitis. The primary outcome measure was the Glasgow outcome scale score at 8 weeks and interaction tests were used to examine subgroup differences. Between June 1993 and December 2001, 301 patients (56% male) were randomly assigned to a treatment group: 157 received dexamethasone and 144 placebo. Although dexamethasone reduced the risk of unfavourable outcome to a greater extent in women (relative risk [RR] 0.42, 95% confidence interval [CI] 0.21-0.86, P = .02) than men (RR 0.79, 95% CI 0.41-1.51, P = .55), on interaction testing (ratio of RR women:men 0.53, 95% CI 0.20-1.39, P = .19) patient sex was not a significant modifier of the effect of dexamethasone.
在患有细菌性脑膜炎的患者中,已发现女性体内炎症标志物的浓度高于男性。为了研究地塞米松反应中的性别差异,我们对一项双盲、随机多中心试验进行了事后分析,该试验比较了地塞米松(10毫克,每日4次,共4天)与安慰剂对成年细菌性脑膜炎患者的疗效。主要结局指标是8周时的格拉斯哥预后量表评分,并采用交互检验来检查亚组差异。在1993年6月至2001年12月期间,301例患者(56%为男性)被随机分配到治疗组:157例接受地塞米松治疗,144例接受安慰剂治疗。尽管地塞米松在女性中降低不良结局风险的程度(相对风险[RR]0.42,95%置信区间[CI]0.21 - 0.86,P = 0.02)大于男性(RR 0.79,95% CI 0.41 - 1.51,P = 0.55),但在交互检验中(女性与男性RR之比为0.53,95% CI 0.20 - 1.39,P = 0.19),患者性别并非地塞米松疗效的显著修饰因素。